arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 8/2010 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    Passing bell for Rosiglitazone (AVANDIA)?

    NEW ON THE MARKET

    COPD: phosphodiesterase-4 inhibitor roflumilast (DAXAS)

    Me too: alpha blocker silodosin (UROREC) for prostatic hyperplasia

    THERAPY FROM A CRITICAL VIEWPOINT

    Bevacizumab (AVASTIN) without benefit in breast cancer
    free

    a-t READER'S QUESTIONS AND COMMENTS

    Novo Nordisk: foregoing profit for the benefit of patients?

    IN BRIEF

    "Flu" vaccines for 2010/11

    Alteplase (ACTILYSE) for acute ischemic stroke

    Celecoxib (CELEBREX) better than diclofenac (VOLTAREN, generics) plus omeprazole (ANTRA, generics)?

    Tranexamic acid (CYKLOKAPRON) use for severe trauma

    SIDE EFFECTS

    Prescription required for topical ketoprofen (e.g. ADVEL pain relieving gel)

    Serious liver injury due to leflunomide (ARAVA)

    Modafinil (VIGIL) soon restricted to narcolepsy only?

    CURRENT ADR NETWORK REPORT

    Liver injury due to dronedarone (MULTAQ)?

    DOCUMENTATION

    Rise and fall of the glitazone rosiglitazone (AVANDIA)

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles